Home > Research > Publications & Outputs > Probing the substrate specificity of Trypanosom...

Electronic data

  • c3ob42164c

    Rights statement: This article is licensed under a Creative Commons Attribution 3.0 Unported Licence.

    Final published version, 562 KB, PDF document

    Available under license: CC BY

Links

Text available via DOI:

View graph of relations

Probing the substrate specificity of Trypanosoma brucei GlcNAc-PI de-N-acetylase with synthetic substrate analogues

Research output: Contribution to Journal/MagazineJournal articlepeer-review

Published
  • Amy S. Capes
  • Arthur Crossman
  • Michael D. Urbaniak
  • Sophie H. Gilbert
  • Michael A. J. Ferguson
  • Ian H. Gilbert
Close
<mark>Journal publication date</mark>2014
<mark>Journal</mark>Organic and Biomolecular Chemistry
Issue number12
Volume2014
Number of pages16
Pages (from-to)1919-1934
Publication StatusPublished
Early online date12/02/14
<mark>Original language</mark>English

Abstract

A series of synthetic analogues of 1-d-(2-amino-2-deoxy-α-d-glucopyranosyl)-myo-inositol 1-(1,2-di-O-hexadecanoyl-sn-glycerol 3-phosphate), consisting of 7 variants of either the d-myo-inositol, d-GlcpN or the phospholipid components, were prepared and tested as substrates and inhibitors of GlcNAc-PI de-N-acetylase, a genetically validated drug target enzyme responsible for the second step in the glycosylphosphatidylinositol (GPI) biosynthetic pathway of Trypanosoma brucei. The d-myo-inositol in the physiological substrate was successfully replaced by cyclohexanediol and is still a substrate for T. brucei GlcNAc-PI de-N-acetylase. However, this compound became sensitive to the stereochemistry of the glycoside linkage (the β-anomer was neither substrate or inhibitor) and the structure of the lipid moiety (the hexadecyl derivatives were inhibitors). Chemistry was successfully developed to replace the phosphate with a sulphonamide, but the compound was neither a substrate or an inhibitor, confirming the importance of the phosphate for molecular recognition. We also replaced the glucosamine by an acyclic analogue, but this also was inactive, both as a substrate and inhibitor. These findings add significantly to our understanding of substrate and inhibitor binding to the GlcNAc-PI de-N-acetylase enzyme and will have a bearing on the design of future inhibitors.

Bibliographic note

This article is licensed under a Creative Commons Attribution 3.0 Unported Licence.